NK Cell Therapy with CD105 Antibody for Colorectal Cancer
Solution Overview
Problem
Current treatments for colorectal cancer, such as bevacizumab, come with significant side effects and toxicities, necessitating the development of more effective and safer therapeutic approaches, particularly in combination with NK cells and monoclonal antibodies.
Innovation Solution
A method involving the use of isolated NK cells and a monoclonal antibody specific for CD105, comprising a full-length, fully human IgG antibody, is developed to enhance the treatment of colorectal cancer, where the antibody is combined with NK cells and a pharmaceutically acceptable carrier to create a pharmaceutical composition for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments like bevacizumab are used for colorectal cancer, then tumor growth can be inhibited, but significant side effects and toxicities occur
Solution Approach 1:
The patent uses CD105 monoclonal antibody as an intermediary that specifically targets tumor blood vessels expressing CD105, thereby selectively inhibiting tumor growth while sparing normal tissues. This targeted approach reduces off-target effects and toxicities compared to conventional systemic treatments like bevacizumab
Solution Approach 2:
The patent combines CD105 monoclonal antibody with NK cells to create a composite therapeutic system. The antibody provides targeted tumor vessel recognition while NK cells deliver cytotoxic activity, creating a synergistic effect that enhances tumor inhibition while reducing the need for high doses of single agents, thereby reducing toxicity
2Reliability
If NK cells are used for cancer treatment, then direct tumor cell lysis and cytokine secretion occur, but the expansion and persistence of NK cells in vivo is limited
Solution Approach 1:
The CD105 monoclonal antibody acts as a mediator that enhances NK cell function by targeting tumor-associated endothelial cells. This antibody-NK cell combination improves NK cell persistence and effectiveness without requiring excessive NK cell expansion, thereby maintaining anti-tumor activity while improving durability
Solution Approach 2:
The patent modifies the therapeutic approach by changing the parameter of NK cell delivery from high-dose bulk infusion to targeted delivery enhanced by CD105 antibody. This parameter change improves NK cell persistence by concentrating therapeutic activity at the tumor site, reducing clearance, and enhancing local immune microenvironment interactions
3Reliability
If CD105 monoclonal antibody is used at high concentration, then tumor growth inhibition is enhanced, but the complexity of dosing and administration increases
Solution Approach 1:
The CD105 monoclonal antibody serves as a targeted mediator that achieves effective tumor inhibition at lower concentrations compared to non-specific therapies. The targeted binding to CD105-expressing tumor vessels improves therapeutic index, allowing effective dosing with reduced complexity
Solution Approach 2:
The CD105 monoclonal antibody performs multiple functions: it directly inhibits tumor vessel formation, enhances NK cell cytotoxicity, and modulates the tumor microenvironment. This multi-functionality allows a single agent to achieve comprehensive anti-tumor effects without requiring complex combination regimens, simplifying administration
Data Source
AI summary
The present disclosure relates to a method for preparing NK cells and an application thereof in treatment of a cancer. The present disclosure provides a pharmaceutical composition prepared from NK cells and a monoclonal antibody of CD105, which can be used for the treatment of colorectal cancer and has a good application prospect.